Inhibition of ovulation by an oral contraceptive containing 100 mu g levonorgestrel in combination with 20 mu g ethinylestradiol

被引:59
|
作者
Spona, J
Feichtinger, W
Kindermann, C
Wunsch, C
Brill, K
机构
[1] INST STERIL TREATMENT, VIENNA, AUSTRIA
[2] SCHERING AG, GERMAN DIV, D-1000 BERLIN, GERMANY
[3] FIRST DEPT OBSTET & GYNECOL, DIV MOL ENDOCRINOL, VIENNA, AUSTRIA
[4] LUDWIG BOLTZMANN INST EXPT ENDOCRINOL, DIV CELLULAR ENDOCRINOL, VIENNA, AUSTRIA
关键词
oral contraceptives; levonorgestrel; follicle growth;
D O I
10.1016/S0010-7824(96)00183-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Twenty-lour healthy female volunteers with normal ovulatory cycles, aged between 20 and 34 years (27.5 +/- 4.3), were included in a single-center, non-comparative study to investigate the effect on inhibition of ovulation of an oral contraceptive containing 20 mu g ethinylestradiol in combination with 100 mu g levonorgestrel. At baseline, during three treatment cycles and post-treatment, ultrasonography was used to examine the ovaries, to measure follicular size, and to measure the thickness of the endometrium. Serum levels of LH, FSH, estradiol, progesterone, total testosterone, free testosterone, SHBG, and CBG were also measured. Compared with treatment cycle 1, an increase in residual ovarian activity (follicle grades 4-5) was observed in cycles 2 and 3. Mean levels of LH, FSH, 17 beta-estradiol and progesterone remained suppressed during treatment. No escape ovulation was observed during the treatment phase of the study and there were no pregnancies. Ovulation was noted to return rapidly in the posttreatment cycle. Subjective and objective tolerance of the present regimen was noted to be good. Results indicate that the monophasic oral contraceptive containing 100 mu g levonorgestrel combined with 20 mu g ethinylestradiol effectively inhibits ovulation, providing adequate suppression of ovarian activity. (C) 1996 Elsevier Science Inc.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [1] A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel
    Jespersen, J
    Endrikat, J
    Düsterberg, B
    Schmidt, W
    Gerlinger, C
    Wessel, J
    Sidelmann, JJ
    Skouby, SO
    CONTRACEPTION, 2005, 72 (02) : 98 - 104
  • [2] A new low-dose monophasic combination oral contraceptive (Alesse(TM)) with levonorgestrel 100 mu g and ethinyl estradiol 20 mu g
    Archer, DF
    Maheux, R
    DelConte, A
    OBrien, FB
    Adams, D
    Appel, T
    Brown, D
    Carr, B
    Chenault, B
    Connell, E
    Davila, G
    Donovan, S
    Faguant, R
    Glick, H
    Grimes, D
    Hanson, M
    Harris, JW
    Hume, J
    Kasparian, S
    Katz, D
    Lifson, MS
    Mercer, L
    Merritt, D
    Moore, D
    Schade, G
    Spellacy, W
    Stephenson, CD
    Stewart, SK
    Thorp, JM
    Varner, E
    Wallach, E
    Blanchet, P
    Boroditsky, R
    Choquette, P
    Guilbert, E
    Lefebvre, Y
    Powell, MG
    Ross, S
    Senikas, V
    Young, R
    Yuzpe, A
    CONTRACEPTION, 1997, 55 (03) : 139 - 144
  • [3] A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel
    Endrikat, J
    Blode, H
    Gerlinger, C
    Rosenbaum, P
    Kuhnz, W
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2002, 7 (02) : 79 - 90
  • [4] An investigation of ovulation inhibition with a low-dose combined oral contraceptive containing 75 μg gestodene and 20 μg ethinylestradiol
    Archer, DF
    Gast, MJ
    GYNECOLOGICAL ENDOCRINOLOGY, 1998, 12 : 7 - 12
  • [5] ORAL-CONTRACEPTIVES CONTAINING 20 OR 30 MU-G ETHINYLESTRADIOL AND 150 MU-G DESOGESTREL - PHARMACOKINETICS AND PHARMACODYNAMIC PARAMETERS
    JUNGHOFFMANN, C
    FITZNER, M
    KUHL, H
    HORMONE RESEARCH, 1991, 36 (5-6) : 238 - 246
  • [6] Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone
    Endrikat, J
    Hite, R
    Bannemerschult, R
    Gerlinger, C
    Schmidt, W
    CONTRACEPTION, 2001, 64 (01) : 3 - 10
  • [7] Continuous-Use Ethinylestradiol/Levonorgestrel 20μg/90μgAs an Oral Contraceptive
    Antona J. Wagstaff
    Drugs, 2007, 67 : 2475 - 2479
  • [8] Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)
    Archer, DF
    Maheux, R
    DelConte, A
    O'Brien, FB
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : S39 - S44
  • [9] International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg
    Boerrigter, PJ
    Ellman, H
    Dolker, M
    CLINICAL THERAPEUTICS, 1999, 21 (01) : 118 - 127
  • [10] Modulation of ovarian function by an oral contraceptive containing 30 mu g ethinyl estradiol in combination with 2.00 mg dienogest
    Spona, J
    Feichtinger, W
    Kindermann, C
    Moore, C
    Mellinger, U
    Walter, F
    Graser, T
    CONTRACEPTION, 1997, 56 (03) : 185 - 191